SOC therapy for Acute Lymphoblastic Leukemia (ALL) is centered around consolidative chemoimmunotherapy combinations, which include Blinatumomab (an anti-CD20 monoclonal antibody) and Inotuzumab ozogamicin (an anti-CD22 antibody-drug conjugate). The gene discussed is CD22; the disease is acute lymphoblastic leukemia.